Asymmetry Capital Management L.P. Sells 232,956 Shares of Amicus Therapeutics, Inc. (FOLD)

Asymmetry Capital Management L.P. decreased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 36.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 401,909 shares of the biopharmaceutical company’s stock after selling 232,956 shares during the period. Amicus Therapeutics accounts for about 4.8% of Asymmetry Capital Management L.P.’s holdings, making the stock its 10th largest position. Asymmetry Capital Management L.P. owned about 0.24% of Amicus Therapeutics worth $4,047,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Bank of Nova Scotia acquired a new position in shares of Amicus Therapeutics during the 2nd quarter valued at about $1,944,000. Redmile Group LLC increased its holdings in shares of Amicus Therapeutics by 5.9% during the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after acquiring an additional 668,080 shares during the last quarter. State Street Corp increased its holdings in shares of Amicus Therapeutics by 2.2% during the 2nd quarter. State Street Corp now owns 5,892,564 shares of the biopharmaceutical company’s stock valued at $59,332,000 after acquiring an additional 125,635 shares during the last quarter. Gotham Asset Management LLC acquired a new position in shares of Amicus Therapeutics during the 2nd quarter valued at about $308,000. Finally, Palo Alto Investors LLC increased its holdings in shares of Amicus Therapeutics by 0.7% during the 2nd quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after acquiring an additional 57,800 shares during the last quarter.

Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) traded down 0.21% on Thursday, hitting $14.24. The stock had a trading volume of 1,577,203 shares. The stock’s market capitalization is $2.34 billion. The firm’s 50 day moving average is $14.26 and its 200-day moving average is $10.77. Amicus Therapeutics, Inc. has a one year low of $4.41 and a one year high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. The firm had revenue of $7.16 million for the quarter, compared to the consensus estimate of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same quarter in the previous year, the business earned ($0.40) earnings per share. Equities research analysts expect that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Asymmetry Capital Management L.P. Sells 232,956 Shares of Amicus Therapeutics, Inc. (FOLD)” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/10/12/asymmetry-capital-management-l-p-sells-232956-shares-of-amicus-therapeutics-inc-fold.html.

A number of research analysts have recently commented on the company. J P Morgan Chase & Co reissued an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Robert W. Baird reissued an “outperform” rating and set a $18.00 price objective (up previously from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Chardan Capital reissued a “buy” rating and set a $18.50 price objective (up previously from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a report on Friday, October 6th. Finally, Leerink Swann reissued a “buy” rating and set a $20.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Amicus Therapeutics has an average rating of “Buy” and an average target price of $17.81.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply